

# Najoua Lalaoui

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2473728/publications.pdf>

Version: 2024-02-01

42  
papers

5,077  
citations

147801

31  
h-index

254184

43  
g-index

58  
all docs

58  
docs citations

58  
times ranked

7420  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tankyrase-mediated ADP-ribosylation is a regulator of TNF-induced death. <i>Science Advances</i> , 2022, 8, eabh2332.	10.3	9
2	Ubiquitylation of RIPK3 beyond-the-RHIM can limit RIPK3 activity and cell death. <i>IScience</i> , 2022, 25, 104632.	4.1	3
3	25 years of research put RIPK1 in the clinic. <i>Seminars in Cell and Developmental Biology</i> , 2021, 109, 86-95.	5.0	27
4	The necroptotic cell death pathway operates in megakaryocytes, but not in platelet synthesis. <i>Cell Death and Disease</i> , 2021, 12, 133.	6.3	8
5	Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease. <i>Nature</i> , 2020, 577, 103-108.	27.8	198
6	MLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosis. <i>Nature Communications</i> , 2020, 11, 3151.	12.8	194
7	MK2 Inhibition Induces p53-Dependent Senescence in Glioblastoma Cells. <i>Cancers</i> , 2020, 12, 654.	3.7	5
8	Targeting triple-negative breast cancers with the Smac-mimetic birinapant. <i>Cell Death and Differentiation</i> , 2020, 27, 2768-2780.	11.2	31
9	Viral MLKL Homologs Subvert Necroptotic Cell Death by Sequestering Cellular RIPK3. <i>Cell Reports</i> , 2019, 28, 3309-3319.e5.	6.4	83
10	Antagonism of IAPs Enhances CAR T-cell Efficacy. <i>Cancer Immunology Research</i> , 2019, 7, 183-192.	3.4	68
11	Recent advances in understanding inhibitor of apoptosis proteins. <i>F1000Research</i> , 2018, 7, 1889.	1.6	57
12	Tumor immune evasion arises through loss of TNF sensitivity. <i>Science Immunology</i> , 2018, 3, .	11.9	244
13	Combination of IAP antagonist and IFN $\gamma$ activates novel caspase-10- and RIPK1-dependent cell death pathways. <i>Cell Death and Differentiation</i> , 2017, 24, 481-491.	11.2	43
14	Jekyll & Hyde: The Other Life of the Death Ligand TRAIL. <i>Molecular Cell</i> , 2017, 65, 585-587.	9.7	1
15	â€œDid He Who Made the Lamb Make Thee?â€™™ New Developments in Treating the â€œFearful Symmetryâ€™™ of Acute Myeloid Leukemia. <i>Trends in Molecular Medicine</i> , 2017, 23, 264-281.	6.7	4
16	MK2 Phosphorylates RIPK1 to Prevent TNF-Induced Cell Death. <i>Molecular Cell</i> , 2017, 66, 698-710.e5.	9.7	242
17	Relevance of necroptosis in cancer. <i>Immunology and Cell Biology</i> , 2017, 95, 137-145.	2.3	40
18	Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	148

#	ARTICLE	IF	CITATIONS
19	The TNF Receptor Superfamily-NF- $\kappa$ B Axis Is Critical to Maintain Effector Regulatory T Cells in Lymphoid and Non-lymphoid Tissues. <i>Cell Reports</i> , 2017, 20, 2906-2920.	6.4	115
20	Inhibitor of Apoptosis Proteins (IAPs) Limit RIPK1-Mediated Skin Inflammation. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2371-2379.	0.7	32
21	PD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF. <i>Cell Death and Differentiation</i> , 2017, 24, 1705-1716.	11.2	64
22	Functionally distinct roles for different miR-155 expression levels through contrasting effects on gene expression, in acute myeloid leukaemia. <i>Leukemia</i> , 2017, 31, 808-820.	7.2	46
23	The Pseudokinase MLKL and the Kinase RIPK3 Have Distinct Roles in Autoimmune Disease Caused by Loss of Death-Receptor-Induced Apoptosis. <i>Immunity</i> , 2016, 45, 513-526.	14.3	191
24	Linear ubiquitin chain assembly complex coordinates late thymic T-cell differentiation and regulatory T-cell homeostasis. <i>Nature Communications</i> , 2016, 7, 13353.	12.8	47
25	The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia. <i>Science Translational Medicine</i> , 2016, 8, 339ra69.	12.4	140
26	Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics. <i>Cancer Cell</i> , 2016, 29, 145-158.	16.8	93
27	Autophagy and AML "food for thought". <i>Cell Death and Differentiation</i> , 2016, 23, 5-6.	11.2	9
28	Death Receptor-Induced Apoptosis Signalling Regulation by Ezrin Is Cell Type Dependent and Occurs in a DISC-Independent Manner in Colon Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0126526.	2.5	10
29	The molecular relationships between apoptosis, autophagy and necroptosis. <i>Seminars in Cell and Developmental Biology</i> , 2015, 39, 63-69.	5.0	142
30	TNFR1-dependent cell death drives inflammation in Sharpin-deficient mice. <i>ELife</i> , 2014, 3, .	6.0	232
31	cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner. <i>Blood</i> , 2014, 123, 2562-2572.	1.4	145
32	RIPK1 Regulates RIPK3-MLKL-Driven Systemic Inflammation and Emergency Hematopoiesis. <i>Cell</i> , 2014, 157, 1175-1188.	28.9	492
33	The Pseudokinase MLKL Mediates Necroptosis via a Molecular Switch Mechanism. <i>Immunity</i> , 2013, 39, 443-453.	14.3	958
34	dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8. <i>Cell Death and Differentiation</i> , 2012, 19, 1482-1494.	11.2	142
35	Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells. <i>Haematologica</i> , 2012, 97, 38-46.	3.5	79
36	TRAIL-R4 Promotes Tumor Growth and Resistance to Apoptosis in Cervical Carcinoma HeLa Cells through AKT. <i>PLoS ONE</i> , 2011, 6, e19679.	2.5	57

#	ARTICLE	IF	CITATIONS
37	Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. <i>Cell Death and Differentiation</i> , 2011, 18, 700-711.	11.2	75
38	Colony-stimulating factor-1-induced oscillations in phosphatidylinositol-3 kinase/AKT are required for caspase activation in monocytes undergoing differentiation into macrophages. <i>Blood</i> , 2009, 114, 3633-3641.	1.4	51
39	p53-Mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells. <i>Oncogene</i> , 2008, 27, 4161-4171.	5.9	37
40	TRAIL in cancer therapy: present and future challenges. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 1299-1314.	3.4	148
41	Dynamics of HPV16 DNA load reflect the natural history of cervical HPV-associated lesions. <i>Journal of Clinical Virology</i> , 2006, 35, 270-277.	3.1	60
42	Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2. <i>Molecular and Cellular Biology</i> , 2006, 26, 7046-7055.	2.3	288